← back to search

O. J. L. Loosveld

Erasmus MC · NL
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Colorectal Cancer Surgical Treatments, and Cancer Treatment and Pharmacology.
h-index
22
citations
3,036
works
63
NIH funding
primary concept
Medicine
email

Recent publications

First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases
JAMA Oncology 2024cited by 26position: middledoi
Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group
Annals of Oncology 2024cited by 15position: middledoi
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group
The Lancet Oncology 2023cited by 166position: middledoi
Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial
BMC Cancer 2023cited by 55position: middledoi
Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment
JAMA Surgery 2021cited by 53position: middledoi
A prospective observational registry evaluating clinical outcomes of Radium‐223 treatment in a nonstudy population
International Journal of Cancer 2019cited by 31position: middledoi
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
The Lancet Oncology 2018cited by 573position: middledoi
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study.
Journal of Clinical Oncology 2016cited by 19position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 1 papers (2019–2019) · 1 papers (2019–2019)Wilbert Zwart · Eindhoven University of Technology1 papers (2019–2019)Francesco d’Amore · Aarhus University1 papers (2016–2016)Daphne de Jong · The Netherlands Cancer Institute1 papers (2016–2016)Bronno van der Holt · Hovon1 papers (2016–2016)John B.A.G. Haanen · Nikki-Universal (Japan)1 papers (2019–2019)Rob Fijnheer · Meander Medisch Centrum1 papers (2016–2016)Aart Beeker · Utrecht University1 papers (2019–2019) · 1 papers (2016–2016)Marnix G. E. H. Lam · University Medical Center Utrecht1 papers (2019–2019)Mels Hoogendoorn · Ludwig-Maximilians-Universität München1 papers (2016–2016) · 1 papers (2019–2019) · 1 papers (2019–2019)Peter de Nully Brown · Rigshospitalet1 papers (2016–2016) · 1 papers (2019–2019) · 1 papers (2016–2016) · 1 papers (2019–2019)Josée M. Zijlstra · Amsterdam Neuroscience1 papers (2016–2016) · 1 papers (2016–2016)